ClinicalTrials.gg
RecruitingNCT07329699AIM-FFRUpdated Apr 23, 2026

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

An interventional study of MPFFR or Invasive FFR in Coronary Artery Disease, Chronic Coronary Syndrome and Acute Coronary Syndrome, sponsored by Samsung Medical Center. Recruiting at 23 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,100
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Planned enrollment
5th of 21
2,100 · median 520
Started
2026
with 1 other
No phase
16 of 31
5 open now
Primary completion
2028-12
later than 8 of 13 live
Registered
30th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 30th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.

Read the detailed description

Fractional Flow Reserve (FFR) has been established as the gold standard for determining the functional significance of coronary artery stenosis. Current guidelines have classified FFR as a Class IA recommendation for the assessment of intermediate coronary artery lesions. However, FFR remains underused in daily clinical practice, due to requirement for pressure wire use, hyperemia induction, or prolonged procedural time.

To overcome these limitations, angiography-derived computation of FFR have been widely adopted as wire-free alternatives. These technologies enable functional assessment of coronary stenosis without pressure wires, providing a less invasive and more comfortable alternative to wire-based FFR. Multiple modalities have shown reasonable diagnostic accuracy to predict FFR≤0.80. Among them, Quantitative Flow Ratio (QFR)-guided percutaneous coronary intervention (PCI) demonstrated superior clinical outcome than angiography-guided PCI. Based on these results, QFR-guided PCI is supported by class 1B recommendation from European Society of Cardiology guideline. Nevertheless, angiography-derived FFR also has limitations, primarily related to the technical and workflow demands of the process. Computation of angiography-derived FFR typically requires vessel segmentation, correspondence marking, and 3-dimensional reconstruction from angiographic images, which are time-consuming and subject to operator-dependent variability.

Indeed, recent data shows limitations of angiography-based FFR computation. Study by Ninomiya et al. evaluated five different angiography-derived FFR methods (QFR, vFFR from Pie Medical Imaging, caFFR from Rainmed Ltd, 2D-µFR, and 3D-µFR from Pulse Medical Imaging Technology). Although these angiography-derived FFR methods provided higher discrimination than angiographic stenosis severity to discriminate functionally significant stenosis defined by FFR≤0.80 or instantaneous wave-free ratio≤0.89, the AUC ranged from 0.65 to 0.75. Furthermore, recent FAVOR III Europe trial showed that QFR-guided strategy did not meet non-inferiority to FFR-guided strategy in terms of a composite of death, myocardial infarction, and unplanned revascularization at 12 months. These results support invasive FFR-guided strategy is gold standard method.

Recent advances in Artificial Intelligence (AI) have led to development of automated tools for cardiovascular diagnostics, improving both accuracy and workflow efficiency. The AI-driven angiography-based FFR (Medipixel FFR [MPFFR]) has been developed utilizing AI-based fully automated quantitative coronary angiography (AI-QCA). MPFFR utilizes automated frame selection, AI-based contouring, and real-time modeling, allowing for rapid and accurate physiological assessment without manual segmentation. In previous validation study conducted in Korea (599 vessels from 452 patients who underwent clinically indicated FFR measurement from 5 university hospitals in Korea), Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR vs. QFR: R=0.885 vs. R=0.860, P for comparison=0.011; area under curve to predict FFR≤0.80; 0.949 vs. 0.953, P for comparison=0.631). At a median follow-up of 2 years (interquartile range, 1.6 to 2.6 years), patients with MPFFR≤0.80 had higher risk of target vessel failure than those with MPFFR>0.80 (4.5% vs. 0.8%; adjusted HR, 5.94; 95% CI, 1.27-27.91; P=0.024). C-index to predict target vessel failure was comparable between MPFFR and QFR (0.770 vs. 0.753, P for comparison=0.469).

However, whether MPFFR-guided PCI can be used in daily practice still needs to be validated by randomized controlled trial using invasive FFR-guided PCI as reference standard. On this background, the current trial aims to compare clinical outcomes between MPFFR-guided PCI and invasive FFR-guided PCI in patients with coronary artery disease.

03

Conditions studied

  • Coronary Artery Disease
  • Chronic Coronary Syndrome
  • Acute Coronary Syndrome

Keywords

  • Coronary artery stenosis
  • Fractional flow reserve
  • Prognosis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 19 years of age
  2. Eligible for coronary angiography and/or percutaneous coronary intervention.
  3. Chronic coronary syndrome or acute coronary syndrome (non-culprit vessels only)
  4. Coronary artery disease in one or more native major epicardial vessels or their branches with reference vessel diameter of at least 2.5mm and with visually assessed coronary stenosis in which the physiological severity of the lesion is questionable (typically 40-90% diameter stenosis).
  5. Subject who is able to understand risks, benefits and treatment alternatives and sign voluntarily.

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to provide
  2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents and drug-coated balloons
  3. Patients with coronary artery bypass grafting
  4. Patients who have non-cardiac co-morbid conditions with \<1 year
  5. Patients with cardiogenic shock or cardiac arrest
  6. Patients with severe left ventricular systolic dysfunction ( \<30%)
  7. Patients with severe valvular heart disease requiring open heart surgery
  8. Pregnant or lactating women
  9. Angiographic exclusion criteria

    • Culprit vessel of patients with ST-elevation myocardial infarction (target lesions in non-culprit vessel can be enrolled)
    • Chronic total occlusion (target lesions in vessels without chronic total occlusion can be enrolled)
    • Ostial stenosis in left man coronary artery or right coronary artery
    • Severe tortuosity of any target vessel
    • Severe overlap in the stenosed segment
    • Poor image quality precluding identification of vessel contours
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
2,100 participants (estimated)

Study arms

  • Experimental
    MPFFR-guided PCI group

    In patients randomized to artificial intelligence-driven angiography-based fractional flow reserve (MPFFR)-guided PCI group, MPFFR analysis will be performed using MPFFR-1000 version 2.1.0 (Medipixel Inc., Seoul, Korea). Manual correction can be applied when necessary, however, it will be strongly discouraged by the study protocols. Treatment decisions will be made based on site-measured MPFFR value. Functionally significant stenosis will be defined as MPFFR≤0.80. For lesions with MPFFR≤0.80, PCI will be recommended under current guidelines, however, final decision regarding PCI will be at the discretion of operators. In the MPFFR-guided PCI group, on-site MPFFR value will be used in decision making of revascularization. If PCI is not performed for lesions with MPFFR≤0.80, the specific reasons will be collected in electronic case report form. For lesions with MPFFR\>0.80, PCI will be deferred.

    Diagnostic Test: MPFFR or Invasive FFR

  • Active comparator
    Invasive FFR-guided PCI group

    All invasive FFR measurements will be performed after diagnostic coronary angiography according to a standardized protocol as previously described. A pressure-temperature sensor guide wire (Abbott Vascular, Santa Clara, CA, USA) is positioned at the distal segment of the target lesion. To induce maximal hyperemia state, intravenous infusion of adenosine (140μg/kg/min through a peripheral vein) or intracoronary injection of nicorandil (2mg) will be used. In the presence of drift greater than 0.03 FFR unit, pressure wire will be re-equalized and FFR will be measured again. Functionally significant stenosis will be defined as FFR≤0.80. For lesions with FFR≤0.80, PCI will be recommended under current guidelines, however, final decision regarding PCI will be at the discretion of operators. If PCI is not performed for lesions with FFR≤0.80, the specific reasons will be collected in electronic case report form. For lesions with FFR\>0.80, PCI will be deferred.

    Diagnostic Test: MPFFR or Invasive FFR

Interventions

  • Diagnostic testMPFFR or Invasive FFR

    Functionally significant stenosis will be defined as MPFFR≤0.80 or FFR≤0.80. For lesions with MPFFR≤0.80 or FFR≤0.80, PCI will be recommended under current guidelines, however, final decision regarding PCI will be at the discretion of operators. In the MPFFR-guided PCI group, on-site MPFFR value will be used in decision making of revascularization. If PCI is not performed for lesions with MPFFR≤0.80 or FFR≤0.80, the specific reasons will be collected in electronic case report form. For lesions with MPFFR\>0.80 or FFR\>0.80, PCI will be deferred.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac events (MACE)

    a composite of death from any causes, non-fatal myocardial infarction \[MI\], and clinically indicated unplanned revascularization

    Time frame: 1 year after last patient enrollment

Secondary outcomes

  1. All-cause death

    All-cause death (defined by Academic Research Consortium \[ARC\] II definition)

    Time frame: 1 year after last patient enrollment

  2. Cardiovascular death

    Cardiovascular death (defined by Academic Research Consortium \[ARC\] II definition)

    Time frame: 1 year after last patient enrollment

  3. Non-fatal myocardial infarction (MI)

    Non-fatal MI (according to the Fourth universal definition of MI)

    Time frame: 1 year after last patient enrollment

  4. Target vessel-related MI

    Target vessel-related MI (Target vessel denotes vessels with initially interrogated by MPFFR or invasive FFR)

    Time frame: 1 year after last patient enrollment

  5. Non-target vessel-related MI

    Non-target vessel-related MI (Target vessel denotes vessels with initially interrogated by MPFFR or invasive FFR)

    Time frame: 1 year after last patient enrollment

  6. Clinically indicated unplanned revascularization

    Clinically indicated unplanned revascularization (defined by Academic Research Consortium \[ARC\] II definition)

    Time frame: 1 year after last patient enrollment

  7. Clinically indicated target vessel revascularization

    Clinically indicated target vessel revascularization (Target vessel denotes vessels with initially interrogated by MPFFR or invasive FFR)

    Time frame: 1 year after last patient enrollment

  8. Clinically indicated non-target vessel repeat revascularization

    Clinically indicated non-target vessel repeat revascularization (Target vessel denotes vessels with initially interrogated by MPFFR or invasive FFR)

    Time frame: 1 year after last patient enrollment

  9. Vessel or Stent thrombosis

    Vessel or Stent thrombosis (definite thrombosis defined by Academic Research Consortium \[ARC\] II definition)

    Time frame: 1 year after last patient enrollment

  10. Cardiovascular death or target vessel-related MI

    A composite of Cardiovascular death or target vessel-related MI

    Time frame: 1 year after last patient enrollment

  11. Target vessel failure

    Target vessel failure (TVF, a composite of cardiovascular death, target vessel-related MI, and clinically indicated target vessel revascularization)

    Time frame: 1 year after last patient enrollment

  12. Bleeding according to BARC definition

    Bleeding according to BARC definition

    Time frame: 1 year after last patient enrollment

  13. Cerebrovascular accident (CVA)

    Cerebrovascular accident (CVA) including ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA)

    Time frame: 1 year after last patient enrollment

  14. Contrast volume (including both diagnostic angiography and PCI)

    Contrast volume (including both diagnostic angiography and PCI)

    Time frame: immediately after the intervention/procedure

  15. Procedure time of MPFFR or invasive FFR measurement

    Procedure time of MPFFR or invasive FFR measurement

    Time frame: immediately after the intervention/procedure

  16. Procedure time including the decision-making time for PCI following coronary angiography

    Procedure time including the decision-making time for PCI following coronary angiography

    Time frame: immediately after the intervention/procedure

  17. Number of lesions interrogated

    Number of lesions interrogated by MPFFR or invasive FFR

    Time frame: immediately after the intervention/procedure

  18. Number of used stents or drug-coated balloons

    Number of used stents or drug-coated balloons

    Time frame: immediately after the intervention/procedure

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Reseanable request will be reviwed by the Executive Committee.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication of primary report and prespecified subgroup analysis.

Access criteria: Reseanable request will be reviwed by the Executive Committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 33 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jan 9, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329699
Collaborators
Chonnam National University Hospital, Seoul National University Bundang Hospital, Chung-Ang University Gwangmyeong Hospital, The Catholic University of Korea, Keimyung University Dongsan Medical Center, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Korea University Guro Hospital, Inje University Ilsan Paik Hospital, International St. Mary's Hospital, Kyungpook National University Hospital, Korea University Anam Hospital, Ajou University School of Medicine, Changwon Patima Hospital, Bundang CHA Hospital, Ulsan University Hospital, Gachon University Gil Medical Center, Inje University Haeundae Paik Hospital, Gyeongsang National University Changwon Hospital, Wonkwang University Hospital
Responsible party
Joo Myung Lee (Associate Professor, Samsung Medical Center) — Principal investigator
First posted
Jan 9, 2026
Start date
Mar 18, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 23, 2026

Study contacts

Joo Myung Lee, MD, MPH, PhD
Contact
drone80@hanmail.net
0234102575
Seung Hun Lee, MD, PhD
Contact
lsh8602@naver.com
821064137449
Joo Myung Lee, MD, MPH, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion